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INTRODUCTION 
Behçet’s disease, first introduced by Hulusi is a chronic 
multisystem idiopathic inflammatory disorder. The most common 
clinical presentation of Behçet’s disease is in the form of recurrent Oral 
or genital ulceration, uveitis and skin lesions. Ocular involvement can be 
seen in 70 % of individuals as a remitting – relapsing uveitis. 
 
Ocular Behçet’s causes significant morbidity throughout the world. 
The highest prevalence however has been reported in the Mediterranean 
along with the countries of Far and Middle East. Males are typically 
more commonly affected, though geographic location plays a role in the 
variation between sexes. 
 
The pathology that underlies Behçet’s disease is in the form of a 
necrotizing and obliterative vasculitis affecting veins as well as arteries 
of all the organ systems of the body. 
 
Apart from the typical picture, Behçet’s disease may also present 
rarely as extraocular muscle paralysis, conjunctival ulcers, episcleritis, 
scleritis and keratitis 
  
Though certain components of phagocytic system of polymorphonuclear 
leukocytes such as levels of acute phase proteins, erythrocyte 
sedimentation rate, rheumatoid factor, C-reactive protein, neopterin, 
ASO, α 1-antitrypsin, and α 2-macroglobulin tests will help to determine 
the level of disease activity, the diagnosis of Behçet’s disease remains 
clinical as there is no sensitive or specific pathologic finding or 
laboratory diagnosis for definitive diagnosis 1. 
 
There are a substantial number of studies that have been done on 
the clinical picture, visual prognosis and treatment outcome of Behçet’s 
disease. However very few have been done on the Indian population, and 
none have sufficiently covered the South Indian population. 
 
This study was performed at Aravind Eye Hospital and 
Postgraduate institute of Ophthalmology, a tertiary eye care centre in the 
South Indian city of Madurai on patients diagnosed with Behçet’s disease 
and treated here in the last 1 year. 
 
 
 
 
  
EPIDEMIOLOGY 
Behçet’s Disease has been traditionally known to be associated 
with the ‘Silk route’, which includes the Mediterranean and the Middle 
and Far East, but is a cause of ocular morbidity throughout the world. 
 
In the Mediterranean countries, the Middle and Far East the 
prevalence varies between 1/10,000 and 1/1,000. Japan has a prevalence 
Rate of about 1/10,000 with the occurrence more common in the 
temperate northern parts as compared to the subtropical southern parts of 
the country again highlighting the role played by environmental factors. 
The prevalence of Behçet’s disease in Turkey has been found to range 
between 2–42 cases per 10,000 2,3,4 
 
 
 
  
 
Fig.1 : Showing countries with the highest incidence of Behçet’s disease 
 
In Asia, the prevalence varies from 13.5 to 30 per 100,000 which is 
approximately ten per cent of that seen in Turkey. The incidence varies in 
different parts of the world. The incidence (per 100,000 people) in the 
USA is 0.12–0.33, 0.42–0.55 in German natives and 0.64 in the United 
Kingdom. 5,6,7,8 
 
 
 
  
Young adults are typically affected, with prevalence believed to be 
more in males. However the sex ratio varies with geographic location and 
women have been found to be more commonly affected in USA and 
Western Europe9-13.Men usually tend to have a younger age of onset and 
this in turn is related to higher prevalence of ocular disease, and worse 
potential visual acuity. Age and sex however have been found to be 
independent risk factors for the development of visual loss. 14,15Although 
Behçet’s Disease affects primarily young adults, typically presenting in 
the second to fourth decade of life, the onset however can occur at any 
age ranging from infants to the elderly, though it is rarely seen in 
children.16-21 
 
Familial occurrence has been rarely reported with no conjugal 
transmission. There have been reports of lymphocytic antibodies in 
healthy children of parents with Behçet’s disease. Transient neonatal 
Behçet’s disease has also been reported and may be a manifestation of 
circulating immune complexes or autoantibodies. 
 
 
 
 
  
CLASSIFICATION 
 
INTERNATIONAL STUDY CRITERIA 
Recurrent oral ulcerations 
Plus two of: 
· Recurrent genital ulceration 
· Eye lesions 
· Skin lesions 
· Positive Pathergy test 
 
Diagnostic criteria proposed by Behçet Research Committee of Japan 
(1972). 
 
MAJOR CRITERIA 
1. Ocular lesions (iridocyclitis, chorioretinitis and there sequelae) 
2. Recurrent aphthous ulcerations of the oral mucosa 
3. Genital ulcers 
4. Skin lesions (erythema nodosum like eruptions – thrombophlebitis, 
folliculitis, cutaneous hypersensitivity) 
 
  
MINOR CRITERIA 
1. Arthritis 
2. Gastroenteritis 
3. Epididymitis 
4. Vascular symptoms 
5. Neuropsychiatric involvement 
 
TYPES 
1. Complete: all four major criteria simultaneously or at different 
times (ocular lesions are recurrent hypopyon iritis or typical 
retinitis) or three major symptoms simultaneously or at different 
times 
2. Incomplete: Ocular and one major or three minor criteria 
3. Suspect: Two major criteria 
4. Possible: one major criterion 
 
 
 
 
 
 
  
IMMUNOLOGY 
Behçet disease is believed to have an autoimmune origin based on 
its vasculitic nature as well as the cellular characteristics of the infiltrate 
in associated lesions. The main features include perivascular infiltrates 
consisting of lymphomononuclear cells,22,23 swelling/ proliferation of 
endothelial cells which partially obliterate small vessels and lead to 
fibrinoid degeneration.24 
 
Inflammation is believed to be mediated in part with cytokines 
which are associated with the Th1 subset of T lymphocytes. A significant 
number of inflammatory markers have been found to be increased in the 
serum of affected patients. Among these are interleukin IL-8, IL-1B, IL-
18, and TNF.44,45 
 
 
  
 
Fig.2 : Pathogenesis of Uveitis in Behçet’s disease 
Up-regulation of the expression of T-bet has been reported which 
provides further strength to the role of the Th1 subset of T cells in Behçet 
disease.25 
  
Other subsets of T and B cells have also been found to be elevated 
in affected patients. There is an increase in the circulating T cells of 
Behçet patients.26,27 These cells have a role in recognizing autologous as 
well as bacterial antigens. γ – δ T cells are also elevated28 with an 
associated increase in the production of interferon-γ by these cells. 
Finally, there is an increase in the level of activated and memory B cell 
subsets in affected patients29Although there has been found evidence of 
activation of the cellular (T cell) and humoral (B cell) limbs of immune 
response in a number of these patients, the significance of this and the 
exact antigens triggering this response remains unknown. At the cellular 
level, Lehner30 has shown evidence of cell-mediated immunity to 
antigens from oral mucosa. In addition, Rogers et al31 have shown 
increased cell mediated cytotoxicity to cultured oral epithelial cells in 
patients suffering from Behçet disease. Circulating immune complexes 
have been demonstrated by the Raji cell method.32 
 
Other investigators have found circulating antibodies to oral 
mucous membrane antigens, particularly during relapse. 33 Although it is 
provocative to assume that oral mucosal antigens are present inimmune 
complexes, there is no definite evidence supporting this hypothesis. The 
walls of the venules in synovial tissue, studied by immunofluorescence 
  
showed the presence of IgM in the walls of synovial veins and 
capillaries.34 It is however not clear whether the fluorescence seen is due 
to the deposition of IgM or immune complex. 
Other auto-antigens have been proposed, one of them being the 
retinal S antigen.35Weighing against this autoimmune hypothesis 
however is the lack of association with other autoimmune diseases as 
well as the lack of production of more typical organ nonspecific auto-
antibodies like antinuclear antibodies. 
 
PATHOLOGY AND PATHOGENESIS 
The pathogenesis of Behçet disease still continues to be poorly 
understood. 
 
Both environmental and instrinsic factors are believed to play a 
role in the development of the disease. Although the disease is associated 
with HLA-B51 locus, not all people who develop this disease have the 
genotype. 
 
Other genes apart from the HLA locus that can be involved include 
ICAM, TNF and MICA. There is no evident bacterial or viral origin 
though pathogenic candidates have been proposed. Food triggers may 
  
also be associated. The common pathergy skin reaction, though not 
present in all patients, gives an insight into the activation of this disease. 
In this reaction, minor trauma to the skin of affected patients produces a 
rapid inflammatory response which indicates some of the same 
characteristic cellular infiltrates as found in systemic lesions of Behçet 
disease.36 It is hypothesized that, in a genetically susceptible individual, 
all of these potential trigger factors for the disease can cause tissue stress 
or lead to the activation of heat shock proteins, thereby causing the 
induction of Th1 T cell responses, with the characteristic Behçet 
inflammatory response as the end result. 
 
The pathologic changes of Behçet’s disease are a lot better 
understood. The underlying histopathologic lesion common to all organ 
symptoms is a vasculitis primarily involving the venules. 37,38 The chief 
Pathologic features include perivascular infiltrates of mononuclear cells. 
Also, there is swelling/proliferation of endothelial cells leading to 
obliteration of the vessels, fibrinoid degeneration along with surrounding 
tissue necrosis. This cellular infiltrate is similar to that in the skin 
pathergy test.39 Analysis of synovial fluid in affected joints of Behçet 
patients also shows it to be inflammatory in nature, containing a 
moderate number of polymorphonuclear leukocytes. 40 
  
The pathologic changes in Behçet vasculitis in the eye have been 
studied at early as well as late stages.37 In the early stage, the most 
commonly seen feature is vasculitis in the retina and uveal tissues. This 
leads to the occurrence of retinal hemorrhage and neuroretinal 
degeneration. Granulation tissue and fibrous scar formation in the 
vitreous and retina lead to neovascularization at the ora serrata and pars 
plana where cyclitic membranes develop. In the late stages, there is an 
occlusive vasculitic in the vessels of the cyclitic membrane. The 
vasculitis directly results in neuroretinal atrophy and tractional retinal 
detachments of the retina. 
 
 
 
 
 
 
 
 
 
 
 
  
CLINICAL FEATURES 
BD can produce distressing symptoms with systemic involvement 
in varying combinations. It is charecterised by exacerbations and 
remissions and the healing time varies from patient to patient. The 
disease severity tends to diminish as time progresses and may stabilize at 
any moment. It however may become chronic in one of the multiple 
systems involved in its course.41,42,43,44 
 
1. Oral Aphthae 
These are the most universal sign of Behçet’s disease and usually 
the first to appear. A majority of the mild cases present in the form of  
aphthous ulcers involving the oral mucosa and it may not be possible to 
differentiate them  from common aphthae – canker sores, similar in 
appearance and having a necrotic base which is yellowish in colour. 45,46 
 
  
 
Fig.3 : Oral Ulceration seen in patient with Behçet’s Disease 
 
These are often painful and cause a significant amount of 
discomfort. These may progress fast from a tiny flat looking ulcer to a 
large sore. These may occur well before other systemic manifestations 
and the time period between recurrences may be highly variable, between 
weeks to months. These lesions may be found not only on the gums but 
may also be seen on the posterior pharynx, uvula, palate, tongue and the 
lips. They usually heal without scarring in 7 – 10 days, but a significantly 
large ulcer may produce a scar on healing. 
 
  
2. Genital Ulcers 
These are also extremely commonly seen, reported to occur in 
nearly 80–90% cases, and are similar in appearance to oral aphthae. 45,47 
 
 
Fig.4 : Genital ulcers in a male patient 
 
In males the lesions may appear on the scrotum and penis and are 
therefore quite evident, sending the patient for professional help early in 
the disease. Females usually have their lesions on the vulva or on the 
vaginal mucosae. Other lesions may be perianal. Kobayashi and 
colleagues48 reported that lesions on the vulva occur in the premenstrual 
portion of the month. The genital lesions can be deep and therefore leave 
  
scars. Thus an examination of the genital region in a patient with 
suspected Behçet's disease can be useful as signs of old disease may be 
present. 
 
Fig.5 : Genital ulcers in a female patient 
 
These ulcers are usually deeper and larger as compared to mouth 
ulcers, with an onset some time into the disease course 
 
 
 
 
  
3. Skin Lesions 
Skin involvement can be seen in nearly 80% of patients and is seen 
in different combinations through the disease course. 45,49 Papulo-
vesiculo-pustular eruptions along with lesions similar to erythema 
nodosum are seen. These most commonly involve the lower limbs, and 
those involving the anterior surface are the most commonly seen lesions 
and are particularly common in females .50,51 
  
These lesions can however also be seen on the face, neck, buttocks 
and elsewhere. They involute after several weeks without ulceration. 
Acne-like lesions or folliculitis are also commonly seen. These usually 
appear on the back and face. Thrombophlebitis may be found in the 
extremities and denotes a more general life – threatening vascular 
disease. This can be migratory and can occur following an injection or 
even the taking of a blood sample. 
 
  
 
Fig. 6 : Erythema – Nodosum like lesions on the lower extremeties 
 
Cutaneous hypersensitivity is characteristically seen in Behçet's 
disease. The scratching of skin with a needle or even taking a blood 
sample frequently results in a pustule at that site. This phenomenon 
known as Pathergy – has become the basis for the ‘prick’ test, with some 
researchers believing that this could be an important criterion that could 
be used in the diagnosis the disease, as first suggested by Curth 52. 
 
 
 
 
 
  
OCULAR LESIONS 
The eye is the most frequently affected internal organ in Behçet 
Disease. In some patients ocular disease may be present at the outset. 53,54 
The vast majority of patients however have the onset of uveitis at 2 to 4 
years of disease course 
 
In about 1/5th of cases patients present with ocular disease as the 
initial manifestation. It runs a chronic, relapsing course and may show 
bilateral (80 %) or unilateral (20 %) hypopyon, iridocyclitis or 
panuveitis.  
 
Initial attacks have the tendency of being unilateral and more 
anterior. Subsequent attacks tend to involve the vitreous and posterior 
segment, and are more commonly bilateral 
 
Ocular Behçet Disease can be classified into anterior and posterior 
uveitis. This is needed for therapeutic purposes as well prognostication, 
as the involvement of posterior segment indicates a persistent and 
chronic nature, and also a more severe and progressive visual loss. Most 
cases, however, present in the form of panuveitis.  
  
The symptoms the patient presents with, therefore depend on the 
site involved. 
 
a. Anterior Involvement 
The typical presentation in the anterior segment is in the form of 
Recurring and frequently Bilateral Anterior Uveitis which may be mild to 
severe, and can present with blurred vision associated with 
periorbital/global pain, lacrimation and photophobia. Circumcorneal 
ciliary injection and vasodilation are seen associated with a violoaceous 
hue (ciliary flush). The onset may vary from sudden, developing in a 
period of hours or days. 
 
Fig. 7: Circumocorneal Congestion and Hypopyon 
  
It classically produces a recurrent acute relapsing iridocyclitis  
which may persist for up to 2 to 3 months.  
 
On slit lamp examination, cells (leukocytes) can be seen in the 
anterior chamber as a result of inflammation and damage to the vascular 
endothelium, which in turn causes increase in permeablity. 
 
The presence of cells is indicative of active anterior segment 
inflammation. Similarly, flare or Tundall effect caused due protein 
leakage as a result of breakdown of blood – ocular barrier can be 
observed. This may be present even when active inflammation has 
subsided and indicates persistent vascular damage 
 
Keratic precipitates, typically seen on the lower cornea are also a 
frequent manifestation. They are a collection of inflammatory cells, 
typically polymorphonuclear cells and lymphocytes on the endothelium 
of the cornea 
 
Cells may also be seen in the anterior vitreous face. In iritis, cells 
in the aqueous far exceed the number of vitreous cells, whereas it is vice 
versa in intermediate uveitis.  
  
Patients with chronic uveitis may present with floaters and mild 
redness associated with mild pain and photophobia. Following recurrent 
attacks of acute iridocyclitis, adhesions may develop between the pupil or 
posterior surface of the iris with the anterior surface of the lens, forming 
posterior synechiae and leading to an irregular and distorted pupil 
 
 
Fig. 8 : Posterior synechiae in a case of Behçet’s Disease 
 
Recurrent inflammation may lead to the formation of a cyclitic 
membrane formation which in turn may lead to the development of 360 
degrees ring synechiae or secclusio pupillae. As a result pupillary block 
secondary angle closure glaucoma may ensue. Similarly, PAS 
  
(peripheral anterior synechiae) may also be seen along with atrophic 
patches on the iris 
 
In some instances, a macrohypopyon may be seen with the naked 
eye, and is caused due to the massive inflammatory and leukocytic 
response. In the others, microhypopyon observed on slit - lamp 
biomicroscopy and angle hypopyon (demonstrated on gonioscopy) may 
be seen .The hypopyon is mobile in Behçet's disease which may move 
with gravity, posture and head movements as the concentration of 
fibrinoid exudates in BD is not very high. Hypopyon may be the 
presenting feature in 6 % of the patients55,56 and may be missed if the 
patient does not present immediately after the attack of acute 
inflammation. 
 
b. Posterior Involvement 
Attacks of retinal vasculitis are dreaded complications of Ocular 
BD. Vitritis and retinal vasculitis  are the most common posterior 
segment manifestations of Behçet's disease and may involve the veins 
(periphlebitis) more commonly than arteries (periarteritis). It is 
charecterised by fluffy white exudates surrounding the vessels and 
eventually result in thrombotic vascular occlusion. 
  
 
Fig. 9 : Retinal Vasculitis seen in Behçet’s disease 
 
Vitritis, on the other hand typically presents with cellular reaction 
in the vitreous and fewer cells in the anterior chamber, in the absence of 
focal lesions in the retina 
 
Retinitis is another common manifestation of ocular Behçet's 
disease and presents in the form of scattered yellowish - white infiltrates 
with indistinct margins causing clouding of the retina which may be 
superficial or deep. Superficial exudates obscure the view of blood 
vessels but are usually transient and self-resolving.  Deep exudates on the 
other hand may lead to vascular occlusions. 
  
The severity and frequency of exacerbations of posterior segment 
inflammation determine the extent of permanent ocular structural damage 
and irreversible visual loss. 
 
Recurrent severe exacerbations of posterior segment inflammation 
determine the extent of permanent ocular structural damage and may lead 
to irreversible visual loss 
 
However, the most common form of presentation of Behçet’s 
disease is Panuveitis, which may present with any or all the 
manifestations listed above 
 
c. Ocular Complications 
Behçet’s disease can give rise to a wide range of ocular 
complications, which contribute to the grave morbidity which is typical 
of uveitis in Behçet’s disease 
Cystoid Macular Edema is reported as the most common 
complication seen in uveitis associated with Behçet’s Disease. 57 Reported 
to be present in approximately half the patients, it may progress to 
chronic macular damage, and finally with coalescence of intra – retinal 
cystoid spaces, lead to the formation of a macular hole. 
  
Elevation of intraocular pressure may be seen. This may occur 
due to multiple mechanisms. These include plugging of the trabecular 
meshwork by inflammatory cells, trabeculitis, peripheral anterior 
synechiae, neovascular glaucoma, seclusio pupillae, and also due to the 
prolonged use of corticosteroids, topical or systemic. 58 Intraocular 
Pressure may also be reduced in some cases due to reduced aqueous 
secretion 
 
Secondary glaucoma was reported in 11% of patients by Elgin et 
al.59 Nearly half these cases were either steroid – induced or due to ocular 
inflammation, one – fourth had angle closure glaucoma associated with 
peripheral anterior synechiae while one-fifth of the patients had 
pupillary- block angle-closure glaucoma. 10% had Neovascularization as  
the cause of glaucoma 
 
Cataract formation can also be induced by inflammation or 
induced by the prolonged usage of corticosteroids. Posterior subcapsular 
cataracts are the most commonly seen form of cataract. Anterior 
subcapsular cataract and Cortical Cataract may also however be seen 
occasionally 
 
  
In advanced cases, iris atrophy may ensue, Vascular occlusion, 
both central as well as Branch Retinal Vein occlusion may be seen. These 
are usually caused by the vasculitic changes, i.e periphlebitis and gliotic 
sheathing of the vessels, macular degeneration may be seen. There may 
be scarring in the retina, which when present in the macular region can 
significantly impair vision . epiretinal membrane is commonly seen. 
Optic disc changes include papillitis, disc edema and optic atrophy in 
advanced cases. Neovascularization of the iris (rubeosis) as well as in 
the disc and elsewhere in the retina may be seen. These in turn can cause 
a vitreous haemorrhage and a secondary tractional retinal detachment 60,61 
 
After recurrent inflammatory episodes, end-stage disease with 
eventual complete blindness may ensue. This is charecterised by optic 
atrophy and sclerosed vessels that look like white cords. Retinal 
pigmentation accompanied by atrophy and scarring in the retina is seen. 
There is diffuse retinal atrophy with variable chorioretinal pigmentation 
and scarring. Untreated cases may also develop phthisis bulbi requiring 
enucleation62,63 
 
 
 
  
OTHER SYSTEMIC MANIFESTATIONS 
  
Behçet disease is a multisysytemic disorder and the other systems 
that may be involved include the following 
 
1). Articular 
This may be present in nearly half the affected patients, and 
typically presents in the form of non – migratory arthritis affecting one or 
two joints. There is arthralgia, occasionally with swelling and redness. 
The inflammation and ulceration can subsequently lead to radiologically 
visible erosion of cartilage of the joint 
 
2). Vascular Involvement 
Vascular involvement is usually seen in the form of superior and 
inferior vena cava thrombosis. Thrombophlebitis may also be seen, 
involving the superficial or deep veins. Arterial involvement is most 
commonly seen in the pulmonary artery, in the form of vasculitis 
affecting the adventitia and media. Other arteries that can be involved 
include the Femoral, Popliteal and Subclavian arteries. 
 
 
  
3). Gastrointestinal 
Liver may be involved in the form of hepatic outflow impairment 
and hepatic vein obstruction. This is secondary to hepatic venous 
thrombosis. Budd – Chiari syndrome or hepatic hemorrhagic infarction 
may also be seen in nearly 2 % individuals 
 
Spleen may be enlarged due to splenic vein thrombosis. Ileum and 
Colon may be involved in the form of an inflammatory vasculitis that can 
be similar in presentation to Crohn’s disease 
 
4). Cardiovascular 
These include disturbances in the conduction system, pericarditis, 
myocarditis, acute myocardial infarction and vascular occlusions and 
aneurysms. Valvular disorders like Mitral and Aortic Regurgitation have 
also been reported rarely 
 
5). Renal 
Microscopic haematuria as well as proteinuria may be seen, and 
rarely patients may progress to focal necrotizing glomerulonephritis or 
diffuse proliferative glomerulonephritis 
 
  
6). Genitourinary 
In about 6 % of patients, epididymitis may be seen. Urinary 
Tuberculosis and non – infective Urethritis may be seen rarely 
 
8). Central Nervous System 
 Central Nervous System Behçet disease presents in the from of 
Cerebral Venous Thrombosis involving either the cerebral veins or the 
dural sinuses. Pappiloedema may be seen and this may mimic Idiopathic 
Intracranial Hypertension. The treatment involves use of steroids, 
heparin, cytotoxic drugs and in severe cases CSF shunting may have to 
be attempted 
Meningoencephalitis may also be seen and occurs as a result of 
small – vessel occlusions. There may also be sixth nerve palsy in case of 
brain stem involvement or occasionally presenting as a false localizing 
sign for increased intracranial tension 
 
  
 
Fig.10 :Grey – matter lesions showing involvement of the Central Nervous 
System in Behçet’s disease 
    
  
  
MANAGEMENT 
Testing for Behçet’s Disease 
At present there is no specific laboratory investigation that can 
accurately diagnose Behçet Disease. HLA B-51 genotype has been used 
for screening in some patients. The sensitivity of association however is 
lacking in the test which renders it to be not useful diagnostically. 
Additionally, the skin pathergy reaction may occasionally be used for 
confirmation in Behçet patients. This procedure involves the intradermal 
injection with a 20-gauge needle, which leads to the development of a 
papular erythematous skin reaction within 48 hours of infection, at the 
site of injection 
 
Fig.11 :Pathergy Test 
 
  
In the 1980s, a test was developed which helped detect antibodies 
against mucosal antigens by indirect immunofluorescene. 64  
 
Serum of Behçet patients was incubated along with other 
retinopathies with tissue sections. These were washed and then overlaid 
with goat antibody to human immunoglobulin and conjugated with 
fluorescein. The serum in patients suffering from Behçet syndrome was 
seen to produce a typical reaction with the epidermal cytoplasm. External 
surface of guinea pig lip showed the strongest reaction; Importantly 
however, the human oral mucosa was also positive, though to a lesser 
degree. On comparison with subjects with Behçet’s disease, it was found 
that 80 % of patients with probable Behçet disease in an American 
population, and 60 % of the patients with definite Behçet disease in a 
Turkish population showed positive staining with this assay. The false 
positivity in normal subjects seen with this test was 6 %.The high cost 
and technical difficulties with this test however limit its widespread use. 
 
 
 
 
 
  
TREATMENT 
 
Various treatment regimens have been attempted in Behçet disease 
and many have shown promising results. None of the agents however has 
emerged as the single most effective treatment modality. The treatment to 
be adapted varies based on individual patient circumstances. Also, the 
disease has a natural unpredictable, intermittent course which makes it 
difficult to evaluate with certainty, of various treatment regiments.  
 
There are some generalities however about various classes of 
medications that can be made. 
 
 
  
 
Fig. : General outline of treatment of uveitis in Behçet’s disease 
Corticosteroids 
Corticosteroids have for a long time had a significant role in 
treating acute manifestations of inflammation in Behçet disease. They act 
  
by their effect on macrophage and neutrophil migration along with the 
activation of lymphocytes. These may be given topically, as injections in 
the periocular region or given systemically. Subtenon’s injections have a 
significant role in the treatment of posterior segment inflammation. 66 
 
Intravenous pulse corticosteroids have been found to be effective 
in treating retinitis causing severe loss of vision. 67 
 
Intravitreal triamcinolone has found application in the treatment of 
CME(Cystoid Macular Edema) .68 Corticosteroids may also be applied in 
the form of mouthwash or cream for the treatment of ulcers and relieve 
pain. Intra articular injection of corticosteroids is also occasionally done 
 
Systemic administration finds a significant role in patients 
presenting with severe thrombophlebitis and vasculitis, CNS 
involvement, or retinal neovascularization.66,69 
 
Acute manifestations can be treated by daily administration of 
prednisolone in doses varying from 60 to 100 mg. Once late sequelae 
such as blindness or paralysis have occurred however, they play a limited 
role. 
  
Though corticosteroids form a mainstay of treatment in the acute 
stage, they are not as successful in preventing recurrences. They are 
therefore commonly used in adjunct with other immunosuppressives 
There has been found to be a synergistic role between cyclosporine and 
corticosteroids in the treatment of acute inflammation. 70  
 
In the presence of CNS involvement persistent uveitis not 
responding to administered treatment, a longer duration of corticosteroid 
administration is indicated. Corticosteroids are used in tapering doses as 
an abrupt discontinuation can in turn result in rebound increase in 
intraocular inflammation. However, due to adverse effects, long time use 
of corticosteroids should be avoided. Adverse effects of ocular 
administration include intraocular pressure rise, infection, formation of 
cataract. Side effects associated with systemic administration include 
hypertension, diabetes mellitus, increased chances of infection, 
gastrointestinal ulcers and osteoporosis. 
 
Cyclosporine and FK506 
Cyclosporine and FK506 are now commonly used treatment 
modalities. They act by binding with immunophilins, T cell cytoplasmic 
receptors and in turn lead to immunosuppresion. This mechanism to an 
  
extent explains their additive effect with steroids as both have separate 
mechanisms of action. Studies have shown that cyclosporine decreases 
the severity as well as the frequency of uveitis.71,72 
 
When combined with prednisone, improvement in visual acuity 
was seen in 75% of studied eyes at a follow up period of 2 years.73 
Tacrolimus has also been found to be useful in the treatment of uveitis 74. 
 
The systemic side effect profile however limits the use of both 
medications to severe uveitis. 
 
Cyclosporine is also reported to play a role in the treatment of 
thrombophlebitis and hearing loss, which may be associated with 
Behçet’s disease.72. Concomitant use of cytochrome inhibitors has been 
found to increase the efficacy of treatment with cyclosporine 76 
 
Both cyclosporine as well as Tacrolimus should however not be 
used in patients having Central Nervous System manifestations. They can 
in turn induce neurological adverse effects which include dementia, 
meningo encephalitis and even paralysis.66 
 
  
Cyclosporine has been reported to result in a higher incidence of 
central nervous system involvement and the adverse effects caused by the 
drug can be hard to distinguish with manifestations of neuro-Behçet. 
Nephrotoxicity and hypertension are other side effects associated with 
Behçet’s disease 
 
Cyclophosphamide, Methotrexate, Azathioprine, and Chlorambucil 
Cyclophosphamide and Chlorambucil which are alkylating agents, along 
with the antimetabolites Methotrexate and Azathioprine are used 
primarily in the treatment of severe manifestations, which though 
initially treated with steroids and cyclosporine have not been successfully 
treated. These indications include refractory eye disease and Central 
Nervous System Vasculitis. In a randomized clinical trial which 
compared cyclophosphamide with cyclosporine at a dose of 5 mg/kg/day, 
it was noted that cyclosporine was more effective in terms of visual 
acuity, though this effect could not be maintained at a review period of 2 
years.77  
 
A combination of corticosteroids with cyclosporine and 
azathioprine and remission was seen in some patients. 78 In a large clinical 
trial of azathioprine at a dose of 2.5 mg/kg/d there was found a reduction 
  
not only in the incidence but also in the recurrence rate and severity of 
ocular disease.79 Also, there was found to be a long – term improvement 
in the prognosis of patients with Behçet disease80 
 
It is however, Chlorambucil that is being believed to be the agent 
most effective in the treatment of retinal vasculitis81 and many 
neurologists favor its use for CNS vasculitis as well. 
 
However, as mentioned before, the side effect profile of these 
agents limits their widespread use. These side effects include 
malignancies and hepatotoxicity. Bone marrow suppression and 
infertility are also possible complications. The possiblity of iatrogenic 
teratogenicity must not be neglected as many of these patients are women 
of child – bearing age. 
 
Interferon-α 
Interferon-α has been reported to play a role in the treatment of 
mild to moderate forms of uveitis in Behçet’s disease. It however acts as 
an immunomodulator rather than an immunosupressor. Though not many 
large scale trials have been performed, a large number of small studies 
have reported its efficacy in inducing remission in Behçet patients 
  
One of these studies showed response to treatment in 46 out of 50 
patients having non resolving ocular disease 82.Also, after an average of 
16 months in 20 patients treatment was stopped, and over an observation 
period of 30 month no relapse was seen.82 Interferon-α can also be used 
in the treatment of joint and skin manifestations of Behçet’s disease. A 
clinical trial showed that it was useful in treating oral and genital 
ulcerations and supported its empirical use.83 
 
However, a recurrence of mucocutaneous disease is frequently 
seen once treatment has been discontinued. 
 
The side effect profile of interferon – α has, in most studies not 
been found to be as severe as many other agents. Flu like symptoms are 
commonly seen and may be troublesome in many patients. Severe side 
effects like psychosis and seizures have however been reported.  In the 
clinical trial conducted, 30 % patients had to discontinue interferon – α 
due to toxicity 84 
 
Infliximab 
The use of infliximab in the Behçet disease was first described in 
200128 and since then there have been a significant number of studies 
demonstrating its efficacy.85-89. 
  
The mechanism of action of Infliximab is by inhibition of TNF. 
Though initially it was used only to treat very severe forms of the disease 
and occasionally for gastrointestinal disease, it has now been documented 
to play a significant role in its ability to sustain the patient in a state of 
remission 
 
In a study, the largest conducted so far, of 25 patients, 24 showed 
immediate remission on only a single treatment with this agent. 90 
 
Also, of a total of 15 patients who were given another round of 
treatment over a period of 32 weeks, there were no further recurrences in 
60 %. However, despite the encouraging results so far, data regarding it s 
efficacy and safety over a long-term period is still not adequate. 
Infliximab has also been found to be having an effective role in treating 
non – ocular manifestations of Behçet’s disease, particularly 
mucocutanous ulcers and Central Nervous System disease.91,92 
 
The adverse effect profile of this agent is however incompletely 
known as of now. Retinal Vein Thrombosis and Pulmonary embolism are 
two possible associations that have been documented. 93,94. The 
antithrombotic effect of TNF –  α has been postulated to play a role.95 
  
Surgical Options 
In Behçet disease, phthis bulbi is an unfortunate but commonly 
seen complication. This may be caused either as result of chronic 
inflammation causing degeneration of tissue, or by the detachment of 
ciliary body which in turn may be caused by inflammation or surgical 
intervention. Vitreoretinal surgery has been reported to improve not only 
the visual prognosis but also prevent recurrence in uveitis associated with 
Behçet’s disease96  
 
One such study showed improvement in visual acuity of 5 out of 
10 eyes, from hand movement to finger counting or 3/60 on a Snellen 
scale .97 
 
Also, amongst these 10 eyes, none showed severe postoperative 
inflammation or developed phthisis bulbi. There was also a decrease of 
recurrent inflammatory episodes in these patients.  
 
Behçet’s patients were also found to be well tolerant to 
phacoemulsification cataract surgery. Of 40 eyes studied, 29 showed a 
gain in visual acuity. A total of 18 eyes showed a visual acuity of 20/40 
or better.98 
  
Complications were seen in in 12% to 17% of eyes and included 
severe postoperative inflammation, posterior synechiae formation, and 
cystoid macular edema. Another study showed that the visual outcome 
was to a great extent dependent on the extent of inflammation seen post 
operatively in patients undergoing extracapsular cataract surgery. 99 
 
In patients who underwent surgery without preoperative ocular 
inflammation, there was no significant rise in inflammation 
 
Prognosis 
Behçet’s disease as already mentioned typically shows remissions 
followed by relapses. There is no well defined uniform disease period 
and there is no external factor known yet that can control the period of 
remission in these patients. Mucocutaneous manifestations are the 
commonest to occur and rarely cause significant permanent impairment. 
Morbidity is usually as result of the ocular inflammation, 
thrombophlebitis, arthritis and Central Nervous system and other 
neurologic complications, all of which may be seen in patients with 
Behçet’s disease. Apart from a ruptured aneurysm and severe CNS 
involvement, ocular involvement causes the most distress and 
impairment to the patient. Patients showed predominantly anterior 
  
segment involvement usually show a good prognosis on treatment with 
immunosupressives and as time progress, the frequency of relapses 
lessens and the disease course stabilizes at 15 – 20 years with no further 
attacks. The major causes of disability in patients are blindness which is 
seen in 25 %, and neurological defects along with paralysis which is seen 
in nearly 10 % patients. Death from complications of Behçet’s disease is 
rare, with the commonest causes being severe Central Nervous system 
involvement, ruptured aneurysm and intestinal perforation. 
 
Although the treatment of Behçet disease continues to be a 
struggle, there is significant improvement being made. As we begin to 
understand the disease better and our treatment options continue to 
expand there has been a significant improvement in the treatment 
outcome of patients suffering from Behçet’s disease, particularly in terms 
of preservation of vision.100  
 
With continued research this is expected to improve even further in 
the coming years 
 
 
  
AIMS & OBJECTIVES 
AIM 
To study the clinical picture, visual prognosis and treatment 
outcome of uveitis in Behçet’s disease 
 
OBJECTIVES 
· To study the demographic patterns 
· To the study the pattern of uveitis in Behçet’s disease 
· To study the complications of Behçet’s disease 
· To study the visual outcome 
 
 
 
 
 
 
 
 
 
 
  
MATERIALS AND METHODS 
 
TYPE OF STUDY 
Hospital Based, Observational Prospective Study 
 
INCLUSION CRITERIA 
Patients who met the 1990 classification criteria of the 
International Study Group for Behçet’s disease were included in the 
study. 
 
EXCLUSION CRITERIA 
· Ocular involvement other than uveitis 
· Any history of trauma 
· Patients with uveitis other than Behçet’s disease 
 
METHODOLOGY 
· A detailed history was obtained from each patient which included  
¨ Ocular complaints  
¨ Systemic symptoms 
 
  
· A complete ocular examination was performed at each visit which 
included  
¨ Best corrected visual acuity on a snellen scale 
¨ Slit lamp biomicroscopy 
¨ Tonometry   
¨ Indirect ophthalmoscopy 
 
· Reports from the patient’s primary ophthalmologists, 
dermatologists, and rheumatologists were evaluated and patients 
were referred to the related specialist when required during the 
follow – up visits 
 
· A data form was prepared which collected information on  
¨ Demographics including age at presentation 
¨ Male or female sex  
¨ Extraocular clinical manifestations of Behçet’s disease 
 
· Ophthalmic data recorded which included  
¨ Age at onset of uveitis 
¨ Laterality 
  
¨ Type of uveitis (namely anterior, posterior or panuveitis)  
¨ Ocular findings 
¨ Ocular complications  
¨ Visual acuity 
 
· The treatment advised for each patient was documented 
· The patient was examined on each follow up visit  
 
These findings were then statistically analysed 
 
 
 
 
 
 
 
 
 
 
 
 
  
RESULTS 
This descriptive study included a total of 55 eyes of 30 patients 
and was conducted at the Uvea clinic of Aravind Eye Hospital and 
Postgraduate Institute of Ophthalmology, Madurai in the period of May 
2013 to May 2014 
 
1. Demographic Pattern 
a. Age at presentation 
The mean age of patients in the study was 28.6 with a standard 
deviation of ± 8.8 and the range was 13-49. 
 
b. Age at onset 
The mean age of studied patients at onset was 26.27 ± 9.0 and the 
range was 13-49. 
 
c. Sex 
Of the 30 patients, 28 were male constituting 93.3 % of the 
subjects and 2 were female which constitute 6.7 % of the total study 
subjects 
 
 Sex 
Female 
Male 
Total 
 
 
 
 
93.3%
 
1. Sex 
No. of patients % 
2 6.7 
28 93.3 
30 100 
 
 
6.7%
Sex
Female Male
 
  
2. Complaints 
Complaints 
Complaints No. of eyes % 
Defective vision 
     Present 
     Absent 
 
44 
11 
 
80.0 
20.0 
Pain 
     Present 
     Absent 
 
13 
42 
 
23.6 
76.4 
Watering 
     Present 
     Absent 
 
3 
52 
 
5.5 
94.5 
Photophobia 
     Present 
     Absent 
 
8 
47 
 
14.6 
85.4 
Redness 
     Present 
     Absent 
 
20 
35 
 
36.4 
63.6 
Floaters 
     Present 
     Absent 
 
13 
42 
 
23.6 
76.4 
 
The most common complaint patients presented with was defective 
vision (44 eyes or 80 %), followed by redness (20 eyes or 35 %), pain (13 
eyes or 23.6 %), floaters (13 eyes or 23.6 %), photophobia (8 eyes or 
14.6 %) and watering (3 eyes or 5.5 %) 
  
3. Laterality 
 
Laterality No of patients % 
Unilateral 5 9.1 
Bilateral 25 90.9 
 
In the study, 25 patients (90.9 %) had bilateral presentation 
whereas 5 patients (9.1 %) patients showed unilateral presentation 
 90.9%
 
 
 
 
 
 
9.1%
Laterality
Unilateral Bilateral
 
  
4. Location 
Location No. of eyes % 
Anterior 1 1.8 
Intermediate 1 1.8 
Posterior 1 1.8 
Panuveitis 52 94.6 
Total 55 100 
 
Panuveitis was the presentation in a large majority of patients. Of a 
total of 55 involved eyes, 52 or 94.6 % showed Panuveitis. Anterior 
uveitis was seen in 1 patient (1.8%), Intermediate in 1 patient (1.8%), and 
Posterior uveitis also in 1 patient (1.8%). 
 
 
  
 
 
 
 
 
 
1.8%
0%
20%
40%
60%
80%
100%
Anterior Intermediate
 
1.8% 1.8%
94.6%
Posterior Panuveitis
Location
 
  
5. Duration of first presentation 
The duration of first presentation in our study ranged from 7 to 
3650 days and Median duration of symptoms was 365 days. 
 
6. Severity 
Severity 
 
Severity No. of eyes % 
Mild 7 12.7 
Moderate 17 30.9 
Severe 31 56.4 
Total 55 100 
 
Majority of the patients presented with severe uveitis  (31 eyes or 
56.4 % eyes). 7 (12.7 %) and 17 eyes (30.9 %) showed mild and 
moderate uveitis respectively. 
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7. Chronicity 
 
Chronicity No. of eyes % 
Acute 3 5.4 
Chronic Recurrent 52 94.6 
Total 55 100 
 
The most common presentation was in the form of chronic 
recurrent uveitis, seen in 52 (94.6 %) of eyes. Only 3 eyes (5.4 %) 
showed an acute presentation 
 
 
 
 
 
 
 
 
 
 
 
  
8. Visual acuity 
 
Baseline vision category 
 
Vision category No. of eyes % 
6/6-6/18 29 52.7 
6/24-6/60 7 12.7 
5/60-3/60 6 10.9 
<3/60 13 23.6 
Total 55 100 
  
In our study, at presentation a majority of the patients had a visual 
acuity in the range of 6/6 – 6/18(29 eyes or 52.7 %). 7 patients or 12.7 % 
fell in the range of 6/24 – 6/60, 6 or 10.9 % in 5/60 – 3/60, and 13 eyes or 
23.6 % eyes had a visual acuity of < 3/60 
  
52.7%
Baseline Vision Category
6/6-
 
 
 
 
 
 
 
 
12.7%
10.9%
23.6%
6/18 6/24-6/60 5/60-3/60 <3/60
 
  
Final vision category 
Vision category No of eyes % 
6/6-6/18 31 57.4 
6/24-6/60 8 14.8 
5/60-3/60 2 3.7 
<3/60 13 24.1 
Total 54 100 
 
At final visit, 31 patients (57.4 %) had a visual acuity of 6/6 – 618, 
8(14.8 %) visual acuity of 6/24 – 6/60, 2(3.7 %) were in the range of 5/60 
– 3/60 and 13 patients (24.1 %) had a visual acuity of < 3/60 
 
 
 
 
 
  
57.4%
Final Vision Category
6/6
 
14.8%
3.7%
24.1%
-6/18 6/24-6/60 5/60-3/60 <3/60
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Baseline Vision Category
 
12.7%
10.9%
23.6%
14.8%
3.7%
24.1%
6/24-6/60 5/60-3/60 <3/60
Category 
Final Vision Category
 
  
Best Corrected Visual Acuity 
Log mar 
vision  
N Median (Snellen’s 
equivalent) 
Mean 
(SD) 
Min-Max P-value* 
Baseline 55 0.48(6/18) 0.81(0.9) 0-2.9 
0.481 
Final 54 0.48(6/18) 0.78(0.9) 0-2.9 
 
*Wilcoxon signed rank test 
 
Between the baseline and final visual acuity, the P- value was 
found to be 0.481 which was not found to be statistically significant 
 
There were a total of 7 eyes which showed a visual recovery of 2 
lines or more between the first visit and final visit (12.73 %). Of these, 
the treatment included topical steroids and oral steroids in all 7(100%), 
Methotrexate in 4 eyes (57.14 %), Azathioprine in 1(14.29 %) and 
Colchicine in 2(28.57 %) 
 
 
 
 
 
  
9. Ocular findings – Anterior Segment 
Variable No. of eyes % 
Scleritis 
     Yes 
     No 
 
1 
54 
 
1.8 
98.1 
Conjunctival 
ulcer 
     Yes 
     No 
 
- 
55 
 
- 
100 
Keratitis 
     Yes 
     No 
 
- 
55 
 
- 
100 
Keratic 
Precipitates 
     Yes 
     No 
 
36 
19 
 
65.4 
34.6 
Hypopyon 
     Yes 
     No 
 
9 
46 
 
16.4 
83.6 
Cells 
     Yes 
     No 
 
44 
11 
 
80.0 
20.0 
Flare 
     Yes 
     No 
 
45 
10 
 
81.8 
18.2 
Iris nodules 
     Yes 
     No 
 
1 
54 
 
1.8 
98.2 
Lens status 
     Clear lens 
     Cataract 
     Pseudophakia 
     Aphakia 
 
35 
12 
6 
1 
 
63.6 
21.8 
10.9 
1.8 
Extra ocular 
muscle 
involvement 
     Yes 
     No 
 
 
- 
55 
 
 
- 
100 
 
  
Iridocyclitis presenting as cells and flare was the most commonly 
seen manifestation in our study, seen in 44 (80.0 %) and 45 Eyes (81.8 % 
patients) respectively. 
 
Keratic precipitates were seen in 36 eyes, which constituted 65.4 
% of the eyes 
 
Hypopyon was seen in 9 eyes (16.4 %). 1 eye (1.8 %) showed 
scleritis, and 1 presented with iris nodules (1.8%). None of the patients 
showed conjunctival ulcers, keratitis or extraocular muscle involvement. 
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Anterior Segment
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0.0%
100%
  
Lens status 
Clear lens 
Cataract 
Pseudophakia 
Aphakia 
 
35 
12 
6 
1 
 
63.6 
21.8 
10.9 
1.8 
 
 
The lens was clear in a majority of the eyes studied (35 or 63.6 %), 
showed cataract in 12 (21.8 %), and pseudophakic in 6 eyes (10.9 %). 1 
patient was aphakic. 
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10. Posterior segment 
Posterior segment 
Variable No.of eyes % 
Media 
     Clear 
     Hazy 
 
39 
16 
 
70.9 
29.1 
Vitreous cells 
     Present 
     Absent 
 
49 
6 
 
89.1 
10.9 
Snow bank 
     Present 
     Absent 
 
5 
50 
 
9.1 
90.9 
Snow balls 
     Present 
     Absent 
 
8 
47 
 
14.5 
85.5 
Retinitis 
     Present 
     Absent 
 
13 
42 
 
23.6 
76.4 
Vasculitis 
     Present 
     Absent 
 
35 
20 
 
63.6 
36.4 
Vitreous opacities 
     Present 
     Absent 
 
24 
31 
 
43.6 
56.4 
Neovascularization 
     Present 
     Absent 
 
- 
55 
 
- 
100 
Optic nerve edema 
     Present 
     Absent 
 
7 
48 
 
12.7 
87.3 
Macular edema 
     Present 
     Absent 
 
18 
37 
 
32.7 
67.3 
 
The media was clear in 39 eyes (70.9 %) and hazy in 16 (29.1 %) eyes 
 
  
The most common posterior segment manifestation was in the 
form of vitreous cells seen in 89.1
%) eyes. 
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(49 %) eyes, and vasculitis in 35 (63.6 
29.1%
Hazy
- Media
 
  
Snow balls and snow banking were seen in 5 (9.1 %) and 8 (14.5 
%) patients respectively. 
 
Retinitis was seen in 13 (23.6 %). Vitreous opacities were seen in 
24 (43.6 %) eyes, retinitis in 13 (23.6 %) eyes. Optic nerve edema and 
macular edema were seen in 7(12.7 %) eyes and 18(32.7 %) 
respectively. 
  
None of the patients showed neovascularization of the retina. 
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32.7%
67.3%
  
11. Extraocular manifestations 
 
Extraocular manifestation Present Absent 
Recurrent oral ulcer 28(93.3) 2(6.7) 
Genital ulcer 17(56.7) 13(43.3) 
Arthritis 11(36.7) 19(66.7) 
Skin lesions 4(13.3) 26(86.7) 
Thrombophlebitis - 30(100.0) 
CNS involvement 1(3.3) 29(96.7) 
 
  
Recurrent oral ulceration was present in 28 of the 30 patients 
studied (93.3%). Genital ulceration was the next most common 
manifestation seen in 17 (56.7 %) patients. Arthritis was
%) patients, Skin lesions in 4 (13.3 %) patients, 
only in 1 (3.3 %) patients. 
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96.7%
  
12. Past treatment 
The patient’s previous treatment history was documented and it 
was observed that a large number of patients were undertreated (24 or 
43.6 %). 18 (32.7 %) were adequately treated whereas 13 (23.6 %) had 
received no previous treatment at all. 
 
Past treatment No. of eyes % 
Not treated 13 23.6 
Under treated 24 43.6 
Adequately treated 18 32.7 
Total 55 100 
 
 43.6%
Past Treatment of Patients
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Immunosuppressives Administered to Patients outside Prior to First 
Visit with us 
Immunosuppressive No. of eyes % 
None 32 58.2 
Methotrexate 8 14.5 
Cyclophosphamide 2 3.63 
Azathioprine 5 9.09 
Cyclosporine a 7 12.7 
Colchicine 6 10.9 
Mycophenolate mofetil 1 1.82 
 
  
In the treatment given outside to the patients, 
most commonly used immunosuppressive (8
cyclosporine A (7 or 12.7 %), 
or 9.09 %), Cyclophosphamide (2 or 3.63 %) and Mycophenolate
(1 or 1.82 %)  
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13. Treatment 
USED NOT USED 
38(69.1) 17(30.9) 
51(92.7) 4(7.3) 
18(32.7) 37(67.3) 
 39(70.9) 16(29.1) 
92.7%
32.7%
70.9%
7.3%
67.3%
29.1%
Treatment
Present Absent
 
  
At our centre, Oral steroids were the most commonly used 
treatment regimen (51 or 92.7 %). Immunosupressives were used in 39 or 
70.9%. Posterior subtenon injection of Triamcinolone acetonide were 
administered in 18 eyes (32.7 %) and topical steroids were used in 38 
(69.1 %) of eyes 
 
Immunosuppressive No.of eyes % 
None 14 25.45 
Methotrexate 29 52.72 
Cyclophosphamide 3 5.45 
Azathioprine 6 10.91 
Cyclosporine A 3 5.45 
Colchicine 8 14.54 
Mycophenolate mofetil 4 7.27 
 
  
In those administered immunosupressives, Methotrexate was the 
most common (29 or 52.72 %) followed by 
Azathioprine (6 or 10.91 %), Mycophenolate
cyclosporine A (3 or 5.45 %) and 
5.5%
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14. Complications 
 
Complication Present Absent 
Rubeosis 2(3.6) 53(96.3) 
Anterior synechiae 2(3.6) 53(96.3) 
Posterior synechiae 14(25.5) 41(74.55) 
Cataract 17(30.9) 38(69.1) 
Vitreous haemorrhage 3(5.4) 52(94.6) 
Optic atrophy 5(9.1) 50(90.9) 
Macular edema 16(29.1) 39(70.9) 
Macular degeneration 9(16.4) 46(83.6) 
Macular hole 1(1.8) 54(98.2) 
Epiretinal membrane 17(30.9) 38(69.1) 
Neovascularisation - 55(100) 
Retinal tear - 55(100) 
Retinal detachment 3(5.4) 52(94.6) 
Phthisis bulbi 2(3.6) 53(96.4) 
End stage disease 4(7.3) 51(92.7) 
 
  
The most common complications observed in the study were 
Cataract and epiretinal membrane which were each seen in 17(30.9 %) of 
the eyes. 
 
Synechiae were seen in 16 eyes (29.1 %) where 2 (3.64 %) showed 
anterior synechiae and 14 (25.5 %) showed posterior synechiae. 
 
Macular edema was present in 17(30.9 %) eyes, macular 
degeneration in 9 (16.4 %) eyes, macular hole in 1(1.8 %). 
 
2 patients (3.6 %) showed rubeosis iridis. Optic atrophy was seen 
in 5(9.1 %) eyes Vitreous haemorrhage and retinal detachment were each 
seen in 3(5.4 %) eyes. 
 
4 patients (3.6 %) were seen to have an end stage disease and 2 
patients (3.6 %) developed phthisis bulbi. 
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DISCUSSION 
 
Age Distribution 
In our study the distribution of age of onset in patients varied from 
a range of 13-49 and had Mean of 26.27 with a standard deviation of ± 
9.0. Tutkun et al10 reported a mean of 30 years ranging from 9 years to 72 
years. Barra et al101 reported the mean age of 29.6 years which ranged 
from 9 to 61 years. Uragancioglu et al104reported the mean age of 15.4 ± 
3.3 years from 9 to 27 years. Rohtagi et al reported the mean age of 25.7 
years ranging from 15 to 46 years. Colvard et al103 reported the mean age 
of 33.3 years with a range of 10 to 66 years. 
 
Sex Distribution 
Male to female ratio in our study was 14 : 1. Tutkun et al10 
reported a male : female ratio of 2.1 : 1, males (68%) more frequently 
involved than females (29%) with a male to female ration of 2.5 : 1. 
Uragancioglu et al also reported males outnumbering females by a ratio 
of 2.3 : 1 
 
 
  
Laterality 
Comparative Analysis of Laterality 
Laterality Tutkun et 
al10 
Barra et 
al101 
Uragancioglu 
et al104 
Present 
study 
Unilateral 193(21.9) 2(4.0) 6(16.6) 5(9.1) 
Bilateral 687(78.10) 47(96.0) 30(83.3) 25(90.9) 
 
A large majority of the patients in our study showed bilateral 
presentation (25 patients or 90.9 %). This was comparable to other 
studies including Barra et al101 (96%), Urgancioglu et al (83.3%), Tutkun 
et al10 (21.9 %) 
 
 
 
 
 
 
 
 
  
Extraocular Manifestations 
Comparative analysis of extraocular clinical manifestations 
 
Manifestations Tutkun 
et al10 
Barra 
et al101 
Rohatgi 
et al102 
Colvard 
et al103 
Present 
study 
Recurrent oral 
ulcers 
880(100) 48(98) 19(100) 32(100) 28(93.3) 
Genital ulcers 526(59.8) 27(55.1) 18(94.7) 27(84.0) 17(56.7) 
Arthritis 299(34.0) 22(44.9) 17(89.5) 18(56.0) 11(36.7) 
Erythema 387(55.4) 25(51.0) 11(57.9) 22(69.0) 4(13.3) 
Thrombophlebitis 41(4.7) 2(4.1)   0(0) 
Central Nervous 
system 
37(4.2) 3(6.1)  7(22.0) 1(3.3) 
 
The commonest extraocular manifestation seen in our study was 
recurrent oral ulceration, which was seen in 28(93.3 %) patients. Tutkun 
et al10, Rohatgi et al102, Colvard et al103 reported recurrent oral ulceration 
in all their patients. Barra et al101reported the same in 98 % of the 
patients. 
 
  
Genital ulceration was seen in 17(56.7 %) of our patients, which 
was comparable to that reported by Tutkun et al10 and Barra et al. 
Rohatgi et al and Colvard et al103 reported a higher incidence of 94.7 % 
and 84 % respectively. 
 
Arthritis was seen in 11 of our patients. Tutkun et al10 showed an 
incidence of 34 %, Barra et al101 44.9%, Rohatgi et al102 showed 89.5 % 
and Colvard et al103 showed an incidence of 56 % . 
 
Erythema nodosum was seen in only 4(13.3 %) of our patients. 
Other studies however reported a higher incidence of the same. Tutkun et 
al10 showed 55.4 %, Barra et al101 51.0 %, Rohatgi et al102 57.9 %, and 
Colvard et al103 69 %. 
 
None of our patients showed Thrombophlebitis but the same was 
reported in 4.7 % by Tutkun et al10 and 4.1 % by Barra et al101. 
 
Only 1 of our patients (3.3%) showed Central Nervous system 
involvement, while the same was reported in 4.7 % by Tutkun et al10 and 
4.1 % by Barra et al101. 
 
  
Pattern of Uveitis 
Comparative analysis of type of Uveitis 
 
Type of 
Uveitis 
Tutkun et 
al10 
Uragancioglu 
et al104 
Barra et 
al101 
Present 
study 
Anterior 172(11.0) 5(13.8) 7(14.8) 1(1.8) 
Posterior 452(28.8)   1(1.8) 
Panuveitis 943(60.2) 31(86.2) 42(85.7) 52(94.6) 
 
The most common presentation was of Panuveitis (94.6 %) in our 
study which was consistent with the other studies, showing panuveitis as 
the form of presentation in 60.2 % by Tutkun et al10, 86.2 % by 
Uragancioglu et al104 and 85.7 % by Barra et al101 
 
 
 
 
 
 
 
  
Comparative analysis of Ocular Findings – Anterior Segment 
 
Anterior 
segment 
findings 
Tutkun 
et al10 
Barra et 
al 101 
Rohatgi 
et al102 
Colvard 
et al103 
Present 
study 
Iritis  42(85.7) 2(10.5) 21(65.0) 44(80.0) 
Hypopyon 188(12.0) 17(34.7) 3(15.2) 3(9.3) 9(16.4) 
 
Iritis presenting in the form of cells in the anterior chamber was 
the most common presentation in our study seen in 44(80%) eyes, and 
was consistent with Barra et al101 which showed the same in 85.7 % and 
Colvard et al103in 65 %. Rohatgi et al102 reported iritis in only 10.5 % 
eyes 
 
 
 
 
 
 
 
  
Comparative Analysis of Ocular Findings – Posterior segment 
 
Posterior 
segment 
findings 
Tutkun et 
al10 
Barra et 
al101 
Uragancioglu 
et al104 
Colvard 
et al103 
Present 
study 
Vitritis 1395(89.0) 42(86.0) 32(88.8) 21(65.1) 49(89.1) 
Vasculitis 1395(89.0) 49(100) 59(89.3) 13(40.6) 35(63.6) 
Retinitis 808(51.6)  45(68.2) 17(89.4) 13(23.6) 
Papillitis 86(5.5) 8(16.3)   7(12.7) 
 
Vitritis was the most common posterior segment finding in our 
study seen in 49(89.1 %) eyes. The same was reported in 89.0 % by 
Tutkun et al10, 86 % by Barra et al101, 88.8 % by Uragancioglu et al104, 
65.1 % by Colvard et al103. 
 
 
 
 
 
  
Vasculitis was the second most common finding, seen in 35(63.6 
%) eyes in our study. Tutkun et al10 reported the same in 89.0 %, Barra et 
al101  in 100 %, Uragancioglu et al104 in 89.3 %, Colvard et al103 in      
40.6 %. 
 
Retinitis was seen in 23.6 % eyes in our study, whereas Tutkun et 
al10 reported the same in 51.6 %, Uragancioglu et al104 68.2 %, Colvard et 
al 103 89.4 % 
 
Papillitis was seen in 7(12.7 %) eyes in our study while Tutkun et 
al10 and Barra et al101 reported the same in 5.5 % and 16.3 % respectively 
 
 
 
 
 
 
 
 
 
 
  
COMPLICATIONS 
Complications Tutkun 
et al10 
Barra 
et al101 
Uragancioglu 
et al104 
Present study 
Cataract 604(38.5) 40(41.7) 31(46.9) 17(30.9) 
Synechiae 
Posterior 
409(26.1)  14(21.2) 14(25.5) 
Epiretinal 
membrane 
266(17.0)   17(30.9) 
Macular edema 697(44.5) 6(12.2)  16(29.1) 
Intraocular 
pressure rise 
216(13.8) 0(0) 7(10.6) 13(23.64) 
Optic Atrophy 370(23.6) 18(18.8) 26(39.4) 5(9.1) 
Intravitreal 
hemorrhage 
36(2.3)   3(5.4) 
Retinal 
Detachment 
23(1.4) 0(0) 4(6.1) 3(5.4) 
Macular 
Degeneration 
304(19.4) 15(5.5) 30(45.4) 9(16.4) 
Rubeosis 19(1.2)   2(3.6) 
Phthisis bulbi 28(1.8) 2(2.1) 1(1.5) 2(3.6) 
Corneal opacity   1(1.5) 0(0) 
Neovascularisation 68(4.3)  1(1.5) 0(0) 
Macular hole 41(2.6) 5(5.2)  1(1.8) 
Venous Occlusion 103(6.6) 6(12.2) 1(1.5) 1(1.8) 
 
  
Cataract was the most commonly complication seen in our study 
seen in 30.9 % eyes in our study. The same was reported in 38.5 % by 
Tutkun et al10, 41.7 % by Barra et al101, and 46.9 % by Uragancioglu et 
al104. 
 
Posterior synechiae were seen in 25.5 % patients in our study, 
which was comparable to 26.1 % by Tutkun et al10 and 21.2 % by 
Uragancioglu et al104. 
 
Epiretinal membrane was seen in 30.9 % of our patents while 
Tutkun et al10 reported the same in 17.0 %. 
 
Macular edema was seen in 16(29.1 %) eyes in our study, while 
the incidence was reported as 44.5 % by Tutkun et al10 and 6(12.2 %) by 
Barra et al101. 
 
Our study showed intraocular pressure rise in 13(23.64 %) eyes, 
while it was 13.8 % by Tutkun et and 10.6 % Uragancioglu et al104. 
 
  
Optic atrophy was seen in 9.1 % of our patients, while it was 
higher in other studies reported in 23.6 % by Tutkun et al 10, 18.8 % by 
Barra et al101, 39.4 % by Uragancioglu et al104. 
 
Intravitreal haemorrhage was seen in 3(5.4 %) of eyes in our study, 
whereas Tutkun et al10 showed the same in 2.3 %. 
 
3 eyes (5.4%) showed a retinal detachment in our study while it 
was 1.4 % by Tutkun et al10 and 6.1 % by Ugancioglu et al. 
 
9 eyes (16.4%) were found to have macular degeneration, while 
this varied in the other studies, seen in 19.4 % by Tutkun et al 10, 15.6 % 
by Barra et al101, and Uragancioglu et al104 showing the highest incidence 
of 45.4 %. 
 
Rubeosis was seen in 2 eyes (3.6 %) of our patients while the same 
was reported in 1.2 % by Tutkun et al. 
 
Another 2 patients (3.6 %) developed phthisis bulbi, which was 
seen in 1.8 % by Tutkun et al10, 2.1 % by Barra et al101 and 1.5 % by 
Uragancioglu et al104. 
  
None of our patients presented with a corneal opacity, while it was 
seen in 1.5 % of patients by Uragancioglu et al104. Neovascularisation in 
the retina reported in 4.3 % by Tutkun et al10, and 1.5 % by Uragancioglu 
et al104, was also not seen in any of our patients. 
 
1(1.8 %) of the eyes in our study showed a macular hole, while the 
incidence was marginally higher in other studies (2.6 % by Tutkun et al 10 
and 5.2 % by Barra et al101 
 
Venous occlusion was also seen in only 1 eye (1.8%) in our study, 
while it was seen in 6.6 % in Tutkun et al10, 12.2 % by Barra et al101 , and 
1.5 % by Uragancioglu et al104 
 
VISUAL ACUITY 
In our study, at presentation a majority of the patients had a visual 
acuity in the range of 6/6 – 6/18(29 eyes or 52.7 %). 7 patients or 12.7 % 
fell in the range of 6/24 – 6/60, 6 or 10.9 % in 5/60 – 3/60, and 13 eyes or 
23.6 % eyes were in the range of < 3/60. Tutkun et al10 reported a 
potential visual acuity of 0.1 or less in 400 of 1388 eyes. They also 
reported that of the 998 eyes with a potential visual acuity better than 0.1, 
155(15.6 %) lost useful vision irreversibly during follow up. Barra et 
  
al101 reported that in 38 of the 96 eyes (39.6 %) involved, a visual acuity 
of 20/40 or better was retained. 22 of 96 eyes (22.9 %) had visual acuity 
between 20/50 – 2/200 and 36 of 96 eyes had visual acuity of less 
20/400. 
 
Tutkun et al10 reported that the risk of visual loss increased 
progressively, reaching 25 % at 10 years, and remained constant 
subsequently. Our study period of 1 year was however not sufficient to 
report on the above and would require further follow up 
 
 
 
 
 
 
 
 
 
 
 
 
  
CONCLUSION 
 
Behçet’s disease is a chronic multisystem idiopathic inflammatory 
disorder with grave visual morbidity. Our study aims to study the clinical 
picture, visual prognosis and treatment outcome in uveitis associated 
with Behçet’s Disease. 55 eyes of 30 patients were included in the study. 
In this study, the Mean (SD) age at presentation was 28.6(8.8) with a 
range of 13-49. The Mean (SD) of the age at onset was 26.27(9.0) and 
the range was 13-49. This was consistent with previous literature where 
the age of presentation is most commonly found to be in the 3 rd decade of 
life. 
 
 A total of 28 subjects were male constituting 93.3 % of the 
subjects and 2 were female which constituted 6.7 % of the total study 
subjects. This ratio was higher in our subjects as compared to that of 
some of the other reported data in literature. 
 
 The most common complaint patients presented with was defective 
vision (44 eyes or 80 %). 
 
  
Of the 30 subjects, 25 patients (90.9 %) had bilateral presentation 
whereas 5 patients (9.1 %) patients showed unilateral presentation. 
 
Panuveitis was the form of presentation in 52 or 94.6 % eyes. Also, 
chronic recurrent uveitis was seen in 52 (94.6 %) of eyes. In the anterior 
segment, Iridocyclitis presenting as cells and flare was the most 
commonly seen manifestation in our study, seen in 44 (80.0 %) and 45 
Eyes (81.8 % patients) respectively. 
 
Keratic precipitates were seen in 36 eyes, which constituted 65.4 
% of the eyes, while Hypopyon was seen only in 9 eyes (16.4 %). 
 
The most common posterior segment manifestation was in the 
form of vitreous cells seen in 89.1(49 %) eyes, and vasculitis in 35 
(63.6%) eyes. 
 
Examination of the mucosa is of extremely high significance in 
patients. Recurrent oral ulceration, in our study was present in 28 of the 
30 patients studied (93.3%). Genital ulceration was the next most 
common manifestation seen in 17 (56.7 %) patients. 
  
Oral steroids were the most commonly used treatment regimen (51 
or 92.7 %). Immunosupressives were used in 39 or 70.9%. 
 
In those administered immunosupressives, Methotrexate was the 
most common (29 or 52.72 %) followed by Colchicine (8 or 14.54 %), 
Azathioprine (6 or 10.91 %), Mycophenolate Mofetil (4 or 7.27 %), 
cyclosporine A (3 or 5.45 %) and cyclophosphamide (3 or 5.45 %). 
 
Of the eyes showing a visual improvement of 2 or more lines in 
visual acuity, topical and oral steroids had been used in all of them. The 
immunosuppressive that was most commonly associated with such 
improvement was Methotrexate followed by Colchicine and 
Azathioprine. 
 
The most common complications observed in the study were 
Cataract and epiretinal membrane which were each seen in 17(30.9 %) of 
the eyes. 
 
Despite intensive treatment however, as observed in our study, 
Behçet’s disease continues to have significant ocular morbidity, and 
improvement and even preservation of existing vision requires a 
  
continuous effort along with coordination from other specialists 
including the dermatologist and rheumatologist. 
 
Newer immunologicals have shown promise in the treatment of 
Behçet’s disease. However, due to the enormous burden of cost of such 
agents, they have not yet been able to find a significant place in the 
management of uveitis of Behçet’s disease in our patients as of now. 
 
The treatment outcome however in Behçet’s disease is much better 
than in the last few decades and is likely to improve further with 
continuous research and improvement in treatment modalities, in the 
coming years    
  
CLINICAL PHOTOS 
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KEY TO MASTER CHART 
 
STUDY EYE 
RIGHT EYE = 1 
LEFT EYE = 2 
 
COMPLAINTS 
PRESENT = 1 
ABSENT = 0 
 
LATERALITY 
RIGHT EYE = 1 
LEFT EYE = 2 
BOTH EYES = 3 
 
PATHOLOGY 
GRANULOMATOUS = 1  
NON GRANULOMATOUS = 2 
 
 
 
  
SEVERITY 
MILD =1  
MODERATE = 2 
SEVERE = 3 
 
CHRONICITY 
ACUTE = 1  
CHRONIC RECURRENT = 2 
 
LOCATION 
ANTERIOR = 1 
INTERMEDIATE = 2 
POSTERIOR = 3 
PANUVEITIS = 4 
ANTERIOR SEGMENT MANIFESTATIONS 
PRESENT = 1 
ABSENT = 0 
 
IRIS NODULES 
KOEPPES = 1 
BUSACCA = 2 
  
LENS STATUS 
CLEAR LENS = 1 
CATARACT = 2 
PSEUDOPHAKIA = 3 
APHAKIA = 4 
 
POSTERIOR SEGMENT MANIFESTATIONS 
PRESENT = 1 
ABSENT = 0 
 
MEDIA 
CLEAR = 1 
HAZY = 2 
 
NEOVASCULARISATION 
DISC = 1 
ELSEWHERE = 2 
ABSENT = 0 
 
 
 
  
EXTRAOCULAR MANIFESTATIONS 
PRESENT = 1 
ABSENT = 0 
 
PAST TREATMENT OUTSIDE 
UNDER TREATED = 1 
ADEQUATELY TREATED = 2 
OVER TREATED = 3 
NO TREATMENT = 0 
 
MEDICATION 
STEROID = 1 
IMMUNOSUPPRESSIVE = 2 
BOTH = 3 
IF IMMUNOSUPRESSIVE 
METHOTREXATE = 1 
CYCLOPHOSPHAMIDE = 2 
CHLORAMBUCIN = 3 
AZATHIOPRINE = 4 
CYCLOSPORIN A = 5 
COLCHICINE = 6 
  
MYCOPHENOLATE MOFETIL=7 
OTHERS = 8 
NONE = 0 
TREATMENT 
USED = 1 
NOT USED = 0 
 
IMMUNUPRESSIVE(SPECIFIC) 
METHOTREXATE = 1 
CYCLOPHOSPHAMIDE = 2 
CHLORAMBUCIL = 3 
AZATHIOPRINE = 4 
CYCLOSPORIN A = 5 
COLCHINE = 6 
MYCOPHENOLATE MOFETIL = 7 
OTHERS = 8 
 
COMPLICATIONS 
PRESENT = 1 
ABSENT = 0 
 
  
SYNECHIAE 
ANTERIOR = 1 
POSTERIOR = 2 
 
GLAUCOMA 
ANGLE CLOSURE = 1 
STEROID INDUCED = 2 
NEOVASCULARISATION = 3 
OTHER = 4 
ABSENT = 0 
NEOVASCULARISATION 
1 = DISC 
2 = ELSEWHERE 
0 = ABSENT 
 
VENOUS OCCLUSION 
CENTRAL = 1 
BRANCH = 2 
ABSENT = 0 
 
 
 
  
 
  
  
 
    
